

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE  
UNIVERSITY OF OXFORD

# Rapid Critical Appraisal of RCTs and Systematic Reviews

Dr Dan Lasserson  
Clinical Lecturer  
Centre for Evidence Based Medicine  
University of Oxford  
www.cebm.net

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE  
UNIVERSITY OF OXFORD

Victims of DVT are told that they can't sue

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE  
UNIVERSITY OF OXFORD

## Step 3 in EBM: appraisal

1. Formulate an answerable question
2. Track down the best evidence
3. Critically appraise the evidence for:
  - Validity
  - Impact (size of the benefit)
  - Applicability
4. Integrate with clinical expertise and patient values
5. Evaluate our effectiveness and efficiency
  - keep a record; improve the process

**Clinical Question**  
In people who take long-haul flights does wearing graduated compression stockings prevent DVT?

Prevention of Deep Vein Thrombosis

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE  
UNIVERSITY OF OXFORD

Searching for critical appraisal checklists randomized controlled trials.

11,100 articles (0.40 seconds)

**A CHECKLIST FOR APPRAISING RANDOMIZED CONTROLLED TRIALS**

1. Was the objective of the trial sufficiently described?
2. Was a satisfactory statement given of the diagnostic criteria for entry to the trial?
3. Were concurrent controls used (as opposed to historical controls)?
4. Were the treatments well defined?
5. Was random allocation to treatments used?
6. Was the potential degree of blindness used?
7. Was there a satisfactory statement of criteria for outcome measures? Was a primary outcome measure identified?
8. Were the outcome measures appropriate?
9. Was a pre-study calculation of required sample size reported?
10. Was the duration of post-treatment follow-up stated?
11. Were the treatment and control groups comparable in relevant measures?
12. Were a high proportion of the subjects followed up?
13. Were the drop-outs described by treatment and control groups?
14. Were the side-effects of treatment reported?
15. How were the ethical issues dealt with?
16. Was there a statement adequately describing or referencing all statistical procedures used?
17. What tests were used to compare the outcome in test and control patients?
18. Were 95% confidence intervals given for the main results?
19. Were any additional analyses done to see whether baseline characteristics (prognostic factors) influenced the outcomes observed?
20. Were the conclusions drawn from the statistical analysis justified?

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE  
UNIVERSITY OF OXFORD

**QUESTION:**

Participants

Intervention Group (IG) & Comparison Group (CG)

Outcome

**VALIDITY**

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

**QUESTION:**

Participants

Intervention Group (IG) & Comparison Group (CG)

Outcome

	I	C
	G	G

	+	-
+	A	B
-	C	D

VALIDITY

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

**QUESTION:**

Participants

Intervention Group (IG) & Comparison Group (CG)

Outcome

	I	C
	G	G

	+	-
+	A	B
-	C	D

VALIDITY

Recruitment

Allocation concealment? comparable groups?

Maintenance treated equally? compliant?

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

**QUESTION:**

Participants

Intervention Group (IG) & Comparison Group (CG)

Outcome

	I	C
	G	G

	+	-
+	A	B
-	C	D

VALIDITY

Recruitment

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

**QUESTION:**

Participants

Intervention Group (IG) & Comparison Group (CG)

Outcome

	I	C
	G	G

	+	-
+	A	B
-	C	D

VALIDITY

Recruitment

Allocation concealment? comparable groups?

Maintenance treated equally? compliant?

Measurements blind? OR objective?

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

**QUESTION:**

Participants

Intervention Group (IG) & Comparison Group (CG)

Outcome

	I	C
	G	G


  



	+	-
+	A	B
-	C	D

VALIDITY

Recruitment

Allocation concealment? comparable groups?





Using the PICO to orient us

**Clinical Question**  
In people who take long-haul flights does wearing graduated compression stockings prevent DVT?

ARTICLES

**Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial**

John H Scurr, Samuel J Machin, Sarah Bailey-King, Ian J Mackie, Sally McDonald, Philip D Coleridge Smith

Scurr et al, Lancet 2001; 357:1485-89

**Participants**

Study Setting: volunteers, UK, ? 1990s

Eligible Participants: no previous DVT, > 50 yrs, planned economy air travel 2 sectors > 8 hours

Participants: 200, mean age 61-62 years

Use the **RAMMbo** to check validity

**Was the Study valid?**

- Recruitment**
  - Who did the subjects represent?
- Allocation**
  - Was the assignment to treatments randomised?
  - Were the groups similar at the trial's start?
- Maintenance**
  - Were the groups treated equally?
  - Were outcomes ascertained & analysed for most patients?
- Measurements blinded OR objective**
  - Were patients and clinicians "blinded" to treatment? OR
  - Were measurements objective & standardised?

User Guide. JAMA, 1993

Appraisal checklist - **RAMMbo**

*Things to Do*

**Study biases**

- Recruitment**
  - Who did the subjects represent?
- Allocation**
  - Was the assignment to treatments randomised?
  - Were the groups similar at the trial's start?
- Maintenance**
  - Were the groups treated equally?
  - Were outcomes ascertained & analysed for most patients?
- Measurements**
  - Were patients and clinicians "blinded" to treatment? OR
  - Were measurements objective & standardised?

Study statistics (p-values & confidence intervals)

Guyatt. JAMA, 1993

**Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial**

Randomisation  
Volunteers were randomised by sealed envelope to one of two groups.

**Methods** We recruited 89 male and 142 female passengers over 50 years of age with no history of thromboembolic problems. Passengers were randomly allocated to one of two groups: one group wore class-I below-knee graduated elastic compression stockings, the other group did not. All the passengers made journeys lasting more than 8 h per flight (median total duration 24 h), returning to the UK within 6 weeks. Duplex ultrasonography was used to assess the deep veins before and after travel. Blood samples were analysed for two specific common gene mutations, factor V Leiden (FVL) and prothrombin G20210A (PGM), which predispose to venous thromboembolism. A sensitive D-dimer assay was used to screen for the development of recent thrombosis.

**Findings** 12/116 passengers (10%; 95% CI 4.8–16.0%) developed symptomless DVT in the calf (five men, seven women). None of these passengers wore elastic compression stockings, and two were heterozygous for FVL. Four further patients who wore elastic compression stockings, had varicose veins and developed superficial thrombophlebitis. One of these passengers was heterozygous for both FVL and PGM. None of the passengers who wore class-I compression stockings developed DVT (95% CI 0–3.2%).

Scurr et al, Lancet 2001; 357:1485-89  
Lancet 2001; 357: 1485–89 See Commentary page 1461

**Intervention & Comparison Groups**

Intervention Group  
Below knee compression stockings

Comparison or Control Group (CG):  
no stockings

115 116  
100 100

**Benefits of Randomisation (and Allocation Concealment)**

- Minimises confounding - **known** and **unknown** potential confounders are evenly distributed between study groups
  - reduces bias in those selected for treatment
  - guarantees treatment assignment will not be based on patients' prognosis

**Fair Allocation – balance achieved?**  
Were the groups similar at the start?

- Usually Table 1 in Results section
- Do imbalances favour one treatment?

**Results**  
Volunteers were excluded before randomisation if they did not fulfil the entry requirements or could not attend hospital for investigation both before and after travel (figure). Thus, 231 of 479 volunteers were randomised. 27 passengers were unable to attend for subsequent ultrasound investigation because of ill-health (three), change of travel plans, or inability to keep appointments (24). Two who

	No stockings	Stockings
Number	110	115
Age (mean)	62 (56-68)	61 (56-66)
Number of women (%)	61 (55%)	61 (53%)
Number with varicose veins	41	45
Days of stay	11 (11-32)	16 (11-27)
Hours flying time	22 (18-36)	24 (19-35)
Haemoglobin (g/L)	142 (113-149)	140 (113-147)
WBC (x 10 <sup>9</sup> /L)	5.9 (5.4-7.3)	6.0 (5.4-6.9)
Packed cell volume	0.44 (0.42-0.47)	0.44 (0.41-0.46)
Platelets (x 10 <sup>9</sup> /L)	240 (205-272)	242 (219-299)
Number FVL positive	7	4
Number PGM positive	1	3

Median (interquartile range) shown, unless otherwise indicated. WBC=white blood cells; FVL=factor V Leiden; PGM=prothrombin gene mutation.  
Table 1: Characteristics of study groups

**Allocation Concealment**  
**BEST – most valid technique**

- Central computer randomization

**DOUBTFUL**  
Envelopes, etc

**NOT RANDOMISED**

- Date of birth, alternate days, etc – WHY?

**Appraisal checklist - RAMMbo**

**Study biases**

- Recruitment**
  - Who did the subjects represent?
- Allocation**
  - Was the assignment to treatments randomised?
  - Were the groups similar at the trial's start?
- Maintenance**
  - Were the groups treated equally?
  - Were outcomes ascertained & analysed for most patients?
- Measurements**
  - Were patients and clinicians "blinded" to treatment? OR
  - Were measurements objective & standardised?

Study statistics (p-values & confidence intervals)

Guyatt. JAMA, 1993

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Comparable Groups: the only difference should be the treatments

✓

(i) I C

(ii) I C

Is the difference between I and C because of (i) the intervention or (ii) because the groups were not comparable in the first place?

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Equal treatment in DVT study?

	Number of Participants	
	No Stockings	Stockings
Aspirin	9	11
Hormone replacement therapy	8	16
Thyroxine	6	6
Antihypertensives, including diuretics	10	12
Antipeptic ulcer drugs	8	3

\*Includes additions to usual drugs

**Table 3: All drugs taken by volunteers who attended for examination before and after air travel\***

Scurr et al, Lancet 2001; 357:1485-89

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Effects of non-equal treatment

- Apart from actual intervention - groups should receive identical care!
  - Trial of Vitamin E in pre-term infants (1949)
  - Vit E "prevented" retrolental fibroplasia

Rx: Give placebo in an identical regime, and a standard protocol

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Follow-up in DVT study?

- 231 randomised (115 to stockings; 116 none)
- 200 analysed
  - 27 were unable to attend for subsequent ultrasound
  - 2 were excluded from analysis because they were upgraded to business class
  - 2 were excluded from analysis because they were taking anticoagulants

See figure on page 1486

Scurr et al, Lancet 2001; 357:1485-89

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Maintaining the Randomisation

- Principle 1 (Intention to treat)
  - Once a patient is randomised, s/he should be analysed in the group randomised to - even if they discontinue, never receive treatment, or crossover.
- Principle 2 (adequate followup)
  - "5-and-20 rule of thumb"
  - 5% probably leads to little bias
  - >20% poses serious threats to validity

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### How important are the losses?

- Equally distributed?
  - Stocking group: 6 men, 9 women - 15
  - No stocking group: 7 men, 9 women - 16
- Similar characteristics?
  - No information provided

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Appraisal checklist

*Things to Do*

**Study biases**

1. Recruitment
  - Who did the subjects represent?
2. Allocation
  - Was the assignment to treatments randomised?
  - Were the groups similar at the trial's start?
3. Maintenance
  - Were the groups treated equally?
  - Were outcomes ascertained & analysed for most patients?
4. Measurements
  - Were patients and clinicians "blinded" to treatment? OR
  - Were measurements objective & standardised?

Study statistics (p-values & confidence intervals)

Guyatt. JAMA, 1993

ARTICLE

### Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights

John H Scurr, Samuel J Machin, S...

**Background** The true frequency of deep-vein thrombosis (DVT) in long-haul flights is unknown. We sought to determine the frequency of DVT and the efficacy of graduated elastic compression stockings in preventing DVT in long-haul flights.

**Methods** We recruited 89 male passengers on long-haul flights (median total duration 24 h), returning to the UK within 6 weeks. Duplex ultrasound was used to assess the deep veins before and after travel. Blood samples were analysed for two specific common gene mutations, factor V Leiden (FVL) and prothrombin G20210A (PGM), which predispose to venous thromboembolism. A sensitive D-dimer assay was used to screen for the development of recent thrombosis.

**Findings** 12/116 passengers (10%; 95% CI 4.8–16.0%) developed symptomless DVT in the calf (five men, seven women). None of these passengers wore elastic compression stockings, and two were heterozygous for FVL. Four further patients who wore elastic compression stockings, had varicose veins and developed superficial thrombophlebitis. One of these passengers was heterozygous for both FVL and PGM. None of the passengers who wore class-I compression stockings developed DVT (95% CI 0–3.2%).

Lancet 2001; 357: 1485–89 See Commentary page 1461

**Evaluation**

Most passengers removed their stockings on completion of their journey. The nurse removed the stockings of those passengers who had continued to wear them. A further duplex examination was then undertaken with the technician unaware of the group to which the volunteer had been randomised

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Measures in DVT study?

- Blood was taken from all participants before travel
- All participants had US once before travel (30 had US twice)
- All participants were seen within 48 hr of return flight, were interviewed and completed a questionnaire, had repeat US

Scurr et al. Lancet 2001; 357:1485-89

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Appraisal checklist

*Things to Do*

**Study biases**

1. Recruitment
  - Who did the subjects represent?
2. Allocation
  - Was the assignment to treatments randomised?
  - Were the groups similar at the trial's start?
3. Maintenance
  - Were the groups treated equally?
  - Were outcomes ascertained & analysed for most patients?
4. Measurements
  - Were patients and clinicians "blinded" to treatment? OR
  - Were measurements objective & standardised?
5. Placebo Effect
6. Chance
7. Real Effect

Study statistics (p-values & confidence intervals)

Guyatt. JAMA, 1993

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Measurement Bias

- Objective
- Blinded?
  - Participants?
  - Investigators?
  - Outcome assessors?
  - Analysts?
- Papers should report **WHO** was blinded and **HOW** it was done




Figure 1: The authors: double blindfold versus single blindfold





Figure 2: The authors: blindfold and mask

Schulz and Grimes. Lancet, 2002

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Placebo effect


Trial in patients with chronic severe itching



Treatment	Itching score
Cyproheptadine HCL	~28
Trimeprazine tartrate	~35
No treatment	~50

Treatment vs no treatment for itching





**P-values (Hypothesis Testing) - in DVT study**

- Incidence of DVT
  - Stocking group - 0
  - No Stocking group - 0.12

Risk difference =  $0.12 - 0 = 0.12$  ( $P=0.001$ )

The probability that this result would only occur by chance is 1 in 1000 → **statistically significant**

- Appraisal checklist**
- Things to Do*
- Study biases**
    - 1. Recruitment
      - Who did the subjects represent?
    - 2. Allocation
      - Was the assignment to treatments randomised?
      - Were the groups similar at the trial's start?
    - 3. Maintenance
      - Were the groups treated equally?
      - Were outcomes ascertained & analysed for most patients?
    - 4. Measurements
      - Were patients and clinicians "blinded" to treatment? OR
      - Were measurements objective & standardised?
    - 5. Placebo Effect
    - 6. Chance
    - 7. Real Effect
- Study statistics (p-values & confidence intervals)
- Guyatt. JAMA, 1993

**Confidence Intervals (Estimation) - in DVT study**

- Incidence of DVT
  - Stocking group - 0
  - No Stocking group - 0.12

Risk difference =  $0.12 - 0 = 0.12$   
(95% CI, 0.058 - 0.20)

The true value could be as low as 0.058 or as high as 0.20 - *but is probably closer to 0.12*

**Since the CI does not include the 'no effect' value of '0' → the result is statistically significant**

- Two methods of assessing the role of chance**
- P-values (Hypothesis Testing)
    - use statistical test to examine the 'null' hypothesis
    - associated with "**p values**" - if  $p < 0.05$  then result is **statistically significant**
  - Confidence Intervals (Estimation)
    - estimates the range of values that is likely to include the true value

**Causes of an "Effect" in a controlled trial**

- Who would now consider wearing stockings on a long haul flight?

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE

UNIVERSITY OF OXFORD

A **Systematic Review** is a review of a *clearly formulated question* that uses systematic and explicit methods to *identify, select and critically appraise* relevant research, and to *collect and analyse data* from the studies that are included in the review

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE

UNIVERSITY OF OXFORD

## What is your question?

Search for a systematic review

Does the PICO of the review fit that of your question?

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE

UNIVERSITY OF OXFORD

Most reviews do not pass minimum criteria  
A study of 158 reviews\*

- Only 2 met all 10 criteria
- Median was only 1 of 10 criteria met

\* McAlister Annals of Intern Med 1999

CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE

UNIVERSITY OF OXFORD

## Using Pedometers to Increase Physical Activity and Improve Health

A Systematic Review

Dena M. Bravata, MD, MS  
Crystal Smith-Spangler, MD  
Vandana Sundaram, MPH  
Allison L. Gienger, BA

**Context** Without detailed evidence of their effectiveness, pedometers have recently become popular as a tool for motivating physical activity.

**Objective** To evaluate the association of pedometer use with physical activity and health outcomes among outpatient adults.

- Population
- Intervention
- Comparison
- Outcome(s)


CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE

UNIVERSITY OF OXFORD

## Is the review any good?

### FAST appraisal

- Question – What is the PICO?
- Finding
  - Did they find most studies?
- Appraisal
  - Did they select good ones?
- Synthesis
  - What do they all mean?
- Transferability of results



CEBM  
CENTRE FOR EVIDENCE BASED MEDICINE

UNIVERSITY OF OXFORD

## Do pedometers increase activity and improve health?

- Find: what is your search strategy?
  - Databases?
  - Terms?
  - Other methods?

Do yourself then  
Get neighbour's help

**METHODS**  
**Data Sources and Search Strategies**

In collaboration with a professional librarian, we developed individualized search strategies for 7 databases: MEDLINE (January 1966 to February 2007); and EMBASE, Sport Discus, PsychINFO, Cochrane Library, Thompson Scientific (formerly known as Thompson ISI), and ERIC (January 1966 to May 2006). We used search terms such as pedometer, activity monitor, and step counter. We also reviewed the bibliographies of retrieved articles and relevant conference proceedings and contacted experts in exercise physiology for additional studies.



CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### FIND: Did they find all Studies?

- Check for existing systematic review?
- Good initial search
  - Terms (text and MeSH)
  - At least 2 Databases: MEDLINE, EMBASE, CINAHL, CCTR, ...
- Plus a Secondary search
  - Check references of relevant papers & reviews and
  - Find terms (words or MeSH terms) you didn't use
  - Search again! (*snowballing*)



CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Registered vs Published Studies

Ovarian Cancer chemotherapy: single v combined

	Published	Registered
No. studies	16	13
Survival ratio	1.16	1.05
95% CI	1.06-1.27	0.98-1.12
P-Value	0.02	0.25

Simes, J. Clin Oncol, 86, p1529

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Is finding all published studies enough?


- Negative studies less likely to be published than 'Positive'
- How does this happen?
- Follow-up of 737 studies at Johns Hopkins\*
  - Positive SUBMITTED more than negative (2.5 times)

\*Dickersin, JAMA, 1992

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Which are biased? Which OK?

- All positive studies
- All studies with more than 100 patients
- All studies published in BMJ, Lancet, JAMA or NEJM
- All registered studies



CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Registered vs Published Studies

Ovarian Cancer chemotherapy: single v combined

	Published	Registered
No. studies	16	
Survival ratio	1.16	
95% CI	1.06-1.27	
P-Value	0.02	


Simes, J. Clin Oncol, 86, p1529

CEBM CENTRE FOR EVIDENCE BASED MEDICINE UNIVERSITY OF OXFORD

### Publication Bias: Solution







- All trials registered at inception,
  - The National Clinical Trials Registry: Cancer Trials
  - National Institutes of Health Inventory of Clinical Trials and Studies
  - International Registry of Perinatal Trials
- Meta-Registry of trial Registries
  - [www.controlled-trials.com](http://www.controlled-trials.com)


	"Positive"	"Negative"
<b>Relevance</b>	5.2	4.9
<b>Methods</b>	4.2	2.4
<b>Presentation</b>	4.3	2.6
<b>Summary</b>	3.2	1.8



- Assessment and selection should be:
  - Standardized "Objective" OR
  - Blinded to Results
- Cochrane Handbook has appraisal 'Risk of Bias' guide

\* assessment of quality blind to study outcome





## Weighting studies

- More weight to the studies which give us more information
  - More participants
  - More events
  - More precision
- Weight is proportional to the precision

The figure on the right is from Figure 3. See if you can answer the following questions about this plot.

- How many studies are there?
- How many studies favour treatment?
- How many studies are statistically significant?
- Which is the largest study?
- Which is the smallest study?
- What is the combined result?

MetaView 3.1 - [Death at end of follow up period (Corticosteroids for acute traumatic brain injury)]

Comparison: Any steroid administered in any dose against no steroid  
 Outcome: Death at end of follow up period

Study	Event	Ctrl	Relative Risk (95% CI) (Fixed)	Weight	RR (95% CI) (Fixed)
Alexander 1972	16 / 55	22 / 55	0.73 (0.43, 1.23)	6.6	0.73 (0.43, 1.23)
Braakman 1983	44 / 91	47 / 90	14.2	14.2	0.82 (0.70, 1.21)
Chesson 1987	1 / 5	0 / 5	0.2	0.2	3.00 (0.15, 59.89)
Cooper 1979	26 / 49	13 / 27	5.0	5.0	1.10 (0.69, 1.77)
Davies 1986	33 / 68	21 / 62	6.6	6.6	1.43 (0.84, 2.18)
Faupel 1976	16 / 87	16 / 28	6.8	6.8	0.42 (0.24, 0.71)
Osaki 1994	19 / 133	21 / 136	6.2	6.2	0.83 (0.52, 1.34)
Okinaka 1984	34 / 72	7 / 16	3.4	3.4	1.08 (0.59, 1.98)
Orumbe 1995	38 / 175	49 / 195	13.9	13.9	0.86 (0.60, 1.25)
Henneman 1979	35 / 81	36 / 83	10.7	10.7	1.00 (0.70, 1.41)
PRIS 1980	114 / 201	38 / 74	16.7	16.7	1.10 (0.86, 1.42)
Reinhardt 1972	9 / 17	13 / 18	3.9	3.9	0.73 (0.43, 1.25)
Sauk 1991	8 / 50	9 / 50	2.7	2.7	0.69 (0.37, 1.21)
Stubbs 1989	13 / 38	5 / 34	1.9	1.9	1.43 (0.54, 3.80)
Zagari 1987	4 / 12	4 / 12	1.2	1.2	1.00 (0.25, 3.10)
Zarate 1995	0 / 30	0 / 30	0.0	0.0	Not Estimate
Total (95% CI)	410 / 1194	301 / 925	100.0	100.0	0.96 (0.85, 1.08)

Chi-square 10.11 (df=14) Z=0.66

If we just add up the columns we get 34.3% vs 32.5%, a RR of 1.06, a higher death rate in the steroids group

From a meta-analysis, we get RR=0.96, a lower death rate in the steroids group

## Meta-analysis (Forest) plot

Study	No of patients	Treatment Mean (SD)	No of patients	Control Mean (SD)	Weighted mean difference (fixed effect) (95% CI)	Weight (%)
Dieppe 1980 <sup>8</sup>	12	38.0 (29.0)	12	70.0 (30.0)	7.45	
Gaffney 1995 <sup>9</sup>	42	21.7 (20.7)	42	43.1 (28.7)	36.26	
Jones 1998 <sup>17</sup>	29	48.0 (30.0)	30	57.5 (30.0)	17.71	
Ravaut 1999 <sup>11</sup>	24	23.7 (26.2)	21	45.7 (26.6)	17.36	
Smith 2003 <sup>14</sup>	38	20.8 (30.0)	33	24.7 (30.0)	21.22	
Total (95% CI)	148		138		100.00	

Test for heterogeneity:  $\chi^2=6.87$ ,  $df=4$ ,  $P=0.14$ ,  $I^2=41.7\%$   
 Test for overall effect:  $Z=5.01$ ,  $P=0.00001$

Fig 4 Visual analogue scale for pain up to two weeks after steroid injection in knee

## Transferable? Use in my patients

Is the AVERAGE effect similar across studies?

- If NO, then WHY?
  - Study methods - biases
  - PICO
- If YES, then 2 questions
  - Effect in different individuals?
  - Which version of treatment?





Fig 4 Visual analogue scale for pain up to two weeks after steroid injection in knees

Are the results similar across studies? 3 tests

- “Eyeball” test – do they look the same?
- Test of “Null hypothesis” of no variation (p-value)
- Proportion of variation not due to chance ( $I^2$ )



Cumulative meta-analysis

When did we know that sleeping position affected mortality?




Fig 3: Incidence of antibiotic-associated diarrhea — intention-to-treat analysis. The analysis showed a nonsignificant difference between probiotics and placebo ( $z$  score) and statistically significant heterogeneity.

### Conclusion EBM and Systematic Review


- EBM (quick & dirty)
- Systematic Review

<ul style="list-style-type: none"> <li>• Ask Question</li> <li>• Search</li> <li>• Appraise</li> <li>• Apply</li> </ul>	<ul style="list-style-type: none"> <li>• Ask Question</li> <li>• Search +++++ x 2</li> <li>• Appraise x 2</li> <li>• Synthesize</li> <li>• Apply</li> </ul>
---	---

- Time: 90 seconds
- < 20 articles
- This patient survives!

- Time: 6 months, team
- < 2,000 articles
- This patient is dead

Find a systematic review!! (and appraise it FAST)



### Pros and cons of systematic reviews

- Advantages
  - Larger numbers & power
  - Robustness across PICOs
- Disadvantages
  - May conclude small biases are real effects

